

INTERLEUKIN GENETICS INC  
Form 8-K  
August 28, 2007

## UNITED STATES

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

## FORM 8-K

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) **August 21, 2007**

### **Interleukin Genetics, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

<b>001-32715</b>		<b>94-3123681</b>
(Commission File Number)		(IRS Employer Identification No.)
<b>135 Beaver Street Waltham, MA</b>		<b>02452</b>
(Address of Principal Executive Offices)		(Zip Code)

(781) 398-0700

## Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS**

On August 21, 2007, John M. McCabe, the Controller and Chief Accounting Officer of Interleukin Genetics, Inc. (the Company ) announced his intention to step down from his current positions with the Company to pursue other opportunities, effective August 30, 2007. The Company is actively recruiting a successor.

2

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Interleukin Genetics, Inc.**  
(Registrant)

Date: August 27, 2007

**/s/ THOMAS R. CURRAN, JR.**  
**Thomas R. Curran, Jr.**  
**Interim Chief Executive Officer**  
(Signature)

3

---